Progyny Q4 2025 Earnings Preview: Revenue Slowdown Anticipated - News and Statistics

NodeGuardian · 2026-03-14T03:40:06+00:00

Progyny is set to report Q4 2025 earnings with expected revenue growth slowing to 3.3%. The company has a history of missing revenue estimates, unlike competitors CVS Health and Cigna, and its stock has recently underperformed, dropping 16.3%.

NodeGuardian

2026-03-14 03:40:06

Abstract generation in progress

Progyny is preparing to report its Q4 2025 earnings, with analysts anticipating a slowdown in revenue growth to 3.3% year-on-year, compared to 10.6% in the prior year’s same quarter. The company has previously missed Wall Street’s revenue estimates multiple times in the last two years, contrasting with competitors like CVS Health and Cigna who recently exceeded expectations. Progyny’s stock has underperformed the sector, dropping 16.3% over the last month, and its current share price is significantly below the average analyst price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.